— Exploring the Feasibility of DX/AI Solutions for Bacterial Infections in India —
— Promoting Sustainable International Expansion through the Fusion of Infection Control and Medical DX —
CarbGeM Inc. (Headquarters: Shibuya-ku, Tokyo; CEO: Masakazu Nakajima; hereinafter “CarbGeM”) is pleased to announce that its project, “Feasibility Study on the Introduction and Market Fit of DX/AI Solutions for Bacterial Infections in India” (hereinafter “the Project”), has been selected for the FY2025 Healthcare Industry International Expansion Promotion Program (hereinafter “the Program”), organized by the Ministry of Economy, Trade and Industry (METI) and administered by Medical Excellence JAPAN (MEJ).
This program supports feasibility studies and demonstration projects aimed at the strategic overseas expansion of Japan’s highly competitive healthcare products, services, and technologies. By providing subsidies to healthcare institutions and companies, the program seeks to accelerate the global deployment of Japanese healthcare solutions.
CarbGeM’s initiative will conduct a feasibility study focusing on implementing DX/AI-powered solutions for the diagnosis of bacterial infections in India. The project aims to assess the adaptability and market potential of AI-based diagnostic imaging technologies and a cloud-based AI image analysis platform, and to develop a phased implementation model in alignment with India’s national strategy for AMR (Antimicrobial Resistance). In addition, CarbGeM explores possibilities for joint ventures with local partners.
This initiative seeks to contribute to strengthening India’s infectious disease control efforts, addressing medical personnel shortages, and improving diagnostic accuracy nationwide.
Please refer to the list of selected companies published on the MEJ website.
https://medicalexcellencejapan.org/jp/all/detail/762/ (Japanese website only)
CarbConnect® is a cloud-based digital platform developed by CarbGeM that enables real-time uploading, analysis, and sharing of medical and research images.
Key Features:
▶ Learn more: https://carbgem.com/en/product-en/carbconnect-en/
BiTTE®-iE is a non-medical AI software that estimates bacteria within 10 seconds using AI-based analysis of Gram-stained images. It is designed for research purposes and aids in the early-stage identification of bacterial species, accelerating decision-making in both clinical and research settings.
Key Features:
▶ Learn more: https://carbgem.com/en/product-en/bitte-ie-en/
CarbGeM will continue to promote the deployment of medical DX powered by advanced AI technologies in the Global South, including regions across Asia and Africa. Through international collaboration and open innovation, the company aims to contribute to reducing healthcare disparities and building sustainable healthcare infrastructure worldwide.
CarbGeM is a pioneering technology company committed to advancing diagnostic support, research efficiency, and quality control through innovative software as a medical device (SaMD) and AI-based platforms. We tackle societal challenges such as skilled workforce shortages and regional disparities by providing accurate and rapid solutions for medical and industrial fields.
The company also promotes global cooperation to address challenges such as antimicrobial resistance (AMR), leveraging digital platforms to empower collaboration between researchers and medical professionals.
CarbGeM has been recognized with numerous awards, including the Tokyo Social Innovation Tech Award 2024, and actively engages in open innovation with leading domestic and international research institutions, as well as government-academic-industry partnerships.
